

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Michael J. Davies, et al.

SERIAL NO.: To Be Assigned

:Examiner: To Be Assigned

:Art Unit: To Be Assigned

FILED: Herewith

:

FOR: Treatment of Wounds

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

In the matter of the application being filed herewith, please amend the application as follows, before calculating the filing fee:

In the specification:

Please enter the following sentence as the first paragraph in the specification, immediately following the title:

--This application is filed claiming priority from co-pending United States Provisional Application No. 60/232,669 filed September 15, 2000.--

In the Claims

Cancel claim 2 without waiver of prejudice.

3. (Amended) A method as claimed in claim 1, wherein the inhibitor is administered orally or topically.

4. (Amended) A method as claimed in claim 1, wherein the inhibitor has an IC50 at less than 100 nanomolar.

6. (Amended) A method as claimed in claim 1, wherein the inhibitor is sildenafil.

9. (Amended) A method of treating wounds in a patient which comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor in combination with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), wherein the wound type is selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.

10. (Amended) A method as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

EXPRESS MAIL NO. 86 9117 24217 US

REMARKS

The specification has been amended to state that this application claims priority from provisional application No. 60/232,669, filed September 18, 2000.


The claims have been amended to place them in proper form for U.S. examination. In particular, multiple dependencies have been eliminated. Also, claim 9 has been converted from a European style "use" claim to a method-of-treatment claim in accordance with standard US format. The claim has also been re-worded slightly, to make the claim wording parallel with that of claim 1.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version With Markings To Show Changes"

A Notice of Allowance is courteously solicited.

Respectfully submitted,

Date: AUGUST 10, 2001


James T. Jones
Attorney for Applicant
Reg. No. 30,561

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-4903

09927344-034004

VERSION WITH MARKINGS TO SHOW CHANGES

In the specification:

The following sentence has been entered as the first paragraph immediately following the title:

This application is filed claiming priority from co-pending United States Provisional Application No. 60/232,669 filed September 15, 2000.

Claim 2 has been canceled.

3. A method or use as claimed in claim 1[or 2], wherein the inhibitor is administered orally or topically.
4. A method[or use] as claimed in claim 1 [any preceding claim], wherein the [wherein the] inhibitor has an IC50 at less than 100 nanomolar.
6. A method[or use] as claimed in claim 1 [any preceding claim], wherein the inhibitor is sildenafil.
9. A method of treating wounds in a patient which comprises treating the patient with an effective amount [The use] of a cGMP PDE5 inhibitor in combinatin with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), [for the manufacture of a medicament for the treatment of wounds,] wherein the wound type is selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.
10. A method[Use] as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

69927344-031001